On October 30, 2023, the Department of Health and Human Services (HHS) released a proposed rule establishing penalties for healthcare providers who violate the information blocking.
Designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular.
4D Molecular Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted the RMAT designation for the investigational genetic medicine candidate 4D-150 for intravitreal.
RMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and.